]> 2026-04-12T02:22:45-07:00 SL-701 0 en The vaccine's safety profile is characterized by the absence of severe adverse events, with only mild to moderate reactions observed, making it a potentially safer option for GBM treatment. 2025-01-18T08:27:57Z 2460693.8527431 SL-701 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","SL-701 shows promise in extending overall survival and inducing long-term survival in a subset of patients, particularly those with target-specific CD8+ T cell responses. The vaccine's ability to elicit specific immune responses against GBM antigens underscores its potential as a novel treatment strategy."] SL-701# ERR0de0b09fdf871942cb9b8a10a8978dce 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","A similar approach has been used by Dr. Hideho Okada and colleagues at the University\nof Pittsburgh. In a pilot study using this approach with patients with recurrent tumors\n(162) several major tumor responses were observed. Median survival for the 13 GBM\npatients in the trial was 12 months, with several of the patients still progression-free at the\ntime of the report. A later version of this therapy, called SL-701, consists of three\nshortened peptides corresponding to glioma-associated antigens and is now being tested\nin a phase I\/II trial for HLA-A2 positive recurrent glioblastoma."] SL-701# ERRa3f62c6665776505f0db7c26c19aebf1